Thymidine synthase, thymidine phosphorylase and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

(2010) N C Tebbutt et al.   BRITISH JOURNAL OF CANCER

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

(2009) Y.-K. Kang et al.   ANNALS OF ONCOLOGY

The dual role of thymidine phosphorylase in cancer development and chemotherapy

(2009) Annelies Bronckaers et al.   MEDICINAL RESEARCH REVIEWS

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

(2008) H J Jun et al.   BRITISH JOURNAL OF CANCER

Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy

(2008) M. K. Kim et al.   CLINICAL CANCER RESEARCH

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE